Mutations in the TP53 gene occur in the DNA-binding domain, which resulted in a loss of tumor suppressor function and new gain-of-function mutation promotion, which prevents neoplastic cell death, increases conventional treatment resistance, and boosts tumorigenesis, such as an oncogenic protein [42,43]. The gene discussed is TP53; the disease is neoplasm.